[Studies on cefozopran in the pediatric field]
Related Experiment Videos
Insights
Cefozopran (CZOP) demonstrated favorable pharmacokinetics and high efficacy in pediatric patients. This antibiotic achieved a 94.1% clinical efficacy rate for various infections with a 94.7% bacterial eradication rate.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Background:
- Cefozopran (CZOP) is a cephalosporin antibiotic.
- Pediatric infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefozopran in pediatric patients.
- To assess the safety profile of cefozopran in this population.
Main Methods:
- Pharmacokinetic analysis of cefozopran following intravenous drip infusion at 10 and 20 mg/kg.
- Clinical evaluation of cefozopran in pediatric patients with various infections.
- Assessment of bacterial eradication and adverse events.
Main Results:
- Cefozopran exhibited an average plasma half-life of approximately 1.6-1.8 hours.
- Urinary excretion rates ranged from 53.2% to 56.2%.
- A clinical efficacy rate of 94.1% and a bacterial eradication rate of 94.7% were observed.
Conclusions:
- Cefozopran is effective and well-tolerated for treating pediatric infections.
- The pharmacokinetic profile supports its use in pediatric populations.
- Further monitoring for potential adverse effects like elevated liver enzymes is warranted.
Abstract:
Pharmacokinetic and clinical evaluations of cefozopran (CZOP) were carried out in pediatric patients. The following results were obtained: 1. Upon 30-minute intravenous drip infusion at a dose of 20mg/kg, plasma concentrations of CZOP reached their peaks at the end of drip infusion with an average value of 77.1 micrograms/ml, and the average plasma half-life was 1.78 hours in the beta-phase. Upon 30-minute intravenous drip infusion at a dose of 10 mg/kg, peak plasma concentration was 40.5 micrograms/ml and plasma half-life was 1.62 hours. 2. The urinary excretion rates of CZOP after 30-minute intravenous infusion at doses of 20 and 10 mg/kg were 53.2% and 56.2%, respectively. 3. CZOP was administered to 17 cases (upper and lower respiratory tract infections, pneumonia, lymphadenitis and urinary tract infections) at daily doses of 60-90 mg/kg divided into 3 dosages using 30-minute intravenous drip infusion. Clinical responses were "excellent" in 13 patients, "good" in 3, and "poor" in 1, hence the efficacy rate of 94.1% was obtained. 4. Bacteria identified from various disease cases included 19 strains of 8 species, and the eradication rate was 94.7%. 5. Soft stool occurred in 1 case as an adverse reaction. Laboratory test results showed abnormalities in 2 cases with elevation of GOT and GPT.